CLK2

Across TCGA pan-cancer cohorts, CLK2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CLK2 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CLK2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CLK2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

HNSC, PDAC, and UCEC are the cancer types where CLK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	II,III,IV	0.648	0.909	.014	49	view →
PDAC	DFS	Median	All	0.182	0.622	.002	20	view →
UCEC	DFS	Median	II,III,IV	0.490	0.890	.015	14	view →
LUAD	DFS	Median	All	1.000	0.887	.018	5	view →
LSCC	DFS	Median	II,III,IV	0.880	0.673	.018	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CLK2–HNSC (OS)

Open the HNSC breakdown →